Semaglutide News and Research

Latest Semaglutide News and Research

New 2025 guidelines focus on early intervention and lifestyle to manage high blood pressure

Preventing and managing high blood pressure with healthy lifestyle behaviors, such as following a heart-healthy diet including reducing salt intake, staying physically active, maintaining a healthy weight and managing stress—combined with early treatment with medication to lower blood pressure if necessary—are recommended to reduce the risk of heart attack, stroke, heart failure, kidney disease, cognitive decline and dementia, according to a new clinical guideline published today in the American Heart Association's peer-reviewed journals Circulation and Hypertension, and in JACC, the flagship journal of the American College of Cardiology.

14 Aug 2025

Diabetes drugs linked to higher risk of rare optic nerve damage

...

14 Aug 2025

PFAS exposure increases risk of weight regain after adolescent bariatric surgery

Adolescents who undergo bariatric surgery face a higher risk of weight regain, which can undermine treatment success and long-term health, if they have elevated blood levels of per- and polyfluoroalkyl substances (PFAS) prior to the procedure, according to new USC research.

14 Aug 2025

Research shows GLP-1 drugs safeguard vision despite small retinopathy risk

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, including a reduced risk of blindness. Patients with existing retinopathy on these drugs also needed fewer invasive eye treatments over two years.

13 Aug 2025

Study supports pre-surgery use of GLP-1 RAs for weight reduction

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of surgical complications linked to their obesity, a new study reveals.

12 Aug 2025

Brain’s energy control map offers blueprint for next-gen weight loss therapies

Scientists map how the brain integrates hormonal and neural signals from the body to control appetite, energy use, and reward pathways, revealing targets for next-generation anti-obesity drugs. This review highlights the interplay between neuroendocrine circuits, neuroplasticity, and pharmacotherapy for durable, non-aversive weight loss.

11 Aug 2025

CRISPR screening uncovers microproteins involved in fat storage

The obesity rate has more than doubled in the last 30 years, affecting more than one billion people worldwide.

7 Aug 2025

Updated multidisciplinary European guidelines redefine MASLD diagnosis and treatment

The 2024 European clinical practice guidelines introduce a pivotal terminology shift, replacing NAFLD (non-alcoholic fatty liver disease) with MASLD (metabolic dysfunction-associated steatotic liver disease) and NASH with MASH (metabolic dysfunction-associated steatohepatitis).

7 Aug 2025

LabConnect deploys Sapio LIMS across global operations

Sapio Sciences, the science-aware™ lab informatics platform, today announced the full deployment of Sapio LIMS at LabConnect.

From Sapio Sciences 7 Aug 2025

RAND study highlights patterns of GLP-1 medication use and side effects

Nearly 12% of Americans have used GLP-1 drugs for weight loss, including about one-fifth of women aged 50 to 64, according to a new RAND report.

6 Aug 2025

Immune aging drives the progression of type 2 diabetes

Type 2 diabetes (T2D) is a global metabolic epidemic driven by insulin resistance (IR), chronic inflammation, and β-cell failure.

6 Aug 2025

Research offers hope for weight loss without gastrointestinal distress

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target brain neurons that control appetite but frequently cause side effects.

5 Aug 2025

Weight loss with ozempic may weaken muscles even when size remains stable

As use of the popular anti-diabetic and weight-loss drug Ozempic skyrockets, so have concerns about the medication's side effects.

5 Aug 2025

HIV trial points to semaglutide as a new anti-aging contender

Once-weekly semaglutide significantly slowed epigenetic aging in adults with HIV-associated lipohypertrophy, as measured by multiple DNA methylation clocks in a randomized controlled trial. These exploratory findings suggest GLP-1 receptor agonists could impact biological aging but require further validation in broader populations.

4 Aug 2025

Metformin’s blood sugar control starts in the brain, not just the liver, study finds

Low, clinically relevant doses of metformin lower blood glucose by inhibiting the Rap1 protein in specific neurons of the hypothalamus, revealing a brain-first mechanism. This action is essential for metformin’s effect at therapeutic doses and highlights new directions for diabetes treatment.

3 Aug 2025

Gut bacteria produce hormone-like proteins that regulate weight and blood sugar

Our intestines are home to trillions of microorganisms that produce substances capable of regulating all the body's organs via the bloodstream and the gut's nervous system.

31 Jul 2025

Metformin lowers blood sugar by acting on brain pathways

Although metformin has been the go-to medication to manage type 2 diabetes for more than 60 years, researchers still do not have a complete picture of how it works.

31 Jul 2025

Gut hormone INSL5 linked to chronic diarrhea in patients with bile acid malabsorption

High levels of a hormone found in cells in the gut could underlie many cases of chronic diarrhea and help explain up to 40% of cases of patients with irritable bowel syndrome with diarrhea, according to a new study led by scientists at the University of Cambridge.

29 Jul 2025

Gut microbial metabolites restore hormone-producing cells in obesity

New research from scientists at the Marshall University Joan C. Edwards School of Medicine reveals that certain gut microbial byproducts may hold promise as a novel therapy for obesity-associated metabolic complications by restoring critical hormone-producing cells in the intestine.

29 Jul 2025

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor agonist (GLP-1 RA) medications. Gastrointestinal symptoms were most common, while mental health concerns and tirzepatide-specific side effects were also flagged.

28 Jul 2025

Semaglutide News and Research

Latest Semaglutide News and Research

New 2025 guidelines focus on early intervention and lifestyle to manage high blood pressure

Diabetes drugs linked to higher risk of rare optic nerve damage

PFAS exposure increases risk of weight regain after adolescent bariatric surgery

Research shows GLP-1 drugs safeguard vision despite small retinopathy risk

Study supports pre-surgery use of GLP-1 RAs for weight reduction

Brain’s energy control map offers blueprint for next-gen weight loss therapies

CRISPR screening uncovers microproteins involved in fat storage

Updated multidisciplinary European guidelines redefine MASLD diagnosis and treatment

LabConnect deploys Sapio LIMS across global operations

RAND study highlights patterns of GLP-1 medication use and side effects

Immune aging drives the progression of type 2 diabetes

Research offers hope for weight loss without gastrointestinal distress

Weight loss with ozempic may weaken muscles even when size remains stable

HIV trial points to semaglutide as a new anti-aging contender

Metformin’s blood sugar control starts in the brain, not just the liver, study finds

Gut bacteria produce hormone-like proteins that regulate weight and blood sugar

Metformin lowers blood sugar by acting on brain pathways

Gut hormone INSL5 linked to chronic diarrhea in patients with bile acid malabsorption

Gut microbial metabolites restore hormone-producing cells in obesity

Which GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answers

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Semaglutide News and Research

Latest Semaglutide News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in